← Leaderboards
Thomas A Mace
Ohio State University
$855,000
Attributed
$3,419,998
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2022–25$2M$1.5M$1M$500K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$3,419,998 · 2
By mechanism
R01$3,419,998 · 2
Top collaborators
- Christopher C. Coss4 shared
- Dwight H. Owen4 shared
- Mitch A Phelps4 shared
- Jessica Cooperstone1 shared
- Philip A. Hart1 shared
- Kristen M Roberts1 shared
Most similar at Ohio State University
Same institution · by research overlap
- Electra D. Paskett$38,729,537
- Steven K Clinton$5,749,067
- Steven J Schwartz$1,373,419
- Savita Khanna$981,078
- Cameron Lucian Rink$981,078
Others in their field
Other Rising Stars on “Cells”
- Mari Ostendorf · University Of Washington$51,931,230
- Sabrina Paganoni · Massachusetts General Hospital$30,122,905
- Suma Babu · Massachusetts General Hospital$30,122,905
- Supriya Menezes · The Emmes Company, Llc$25,277,032
- Jinsy Andrews · Columbia University Health Sciences$21,294,649
- Michelle Rives · Baylor College Of Medicine$20,650,593
Research focus
CellsBiological MarkersAnimal ModelCytokineClinical TrialsAffectImmuneCancer PatientResponseMalignant NeoplasmsCheckpoint TherapyClinical PharmacologyAntigen ProcessingCessation Of LifeAntitumor ResponseCachexiaAdvanced DiseaseAnti-Tumor Immune ResponseBone Marrow CellsCancer CachexiaCancer CellCancer EtiologyAlbuminsBone Marrow
Grant awards (5)
Cachexia-mediated FcRn Modulation and Its Impact on Anti-PD1 Therapy in Lung Cancer$1,263,739
R01 · FY2025 · CA
A dietary intervention clinical trial to reduce inflammation and improve outcomes in chronic pancreatitis$306,994
R01 · FY2025 · DK · contact PI
Cachexia-mediated FcRn Modulation and Its Impact on Anti-PD1 Therapy in Lung Cancer$594,010
R01 · FY2024 · CA
Cachexia-mediated FcRn Modulation and Its Impact on Anti-PD1 Therapy in Lung Cancer$615,393
R01 · FY2023 · CA
Cachexia-mediated FcRn Modulation and Its Impact on Anti-PD1 Therapy in Lung Cancer$639,862
R01 · FY2022 · CA